Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Abstract Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize results from an interim analysis of an ongo...

Full description

Bibliographic Details
Main Authors: Henriette Farkas, Marcin Stobiecki, Jonny Peter, Tamar Kinaciyan, Marcus Maurer, Emel Aygören‐Pürsün, Sorena Kiani‐Alikhan, Adrian Wu, Avner Reshef, Anette Bygum, Olivier Fain, David Hagin, Aarnoud Huissoon, Miloš Jeseňák, Karen Lindsay, Vesna Grivcheva Panovska, Urs C. Steiner, Celia Zubrinich, Jessica M. Best, Melanie Cornpropst, Daniel Dix, Sylvia M. Dobo, Heather A. Iocca, Bhavisha Desai, Sharon C. Murray, Eniko Nagy, William P. Sheridan
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Clinical and Translational Allergy
Subjects:
berotralstat
hereditary angioedema
long‐term
prophylaxis
safety
Online Access:https://doi.org/10.1002/clt2.12035

Internet

https://doi.org/10.1002/clt2.12035

Similar Items